Comply with the latest international and domestic standards, and cooperate with the pharmacovigilance system to improve the efficiency of pharmacovigilance work
Provides solutions for drug safety in the clinical trial phase, and supports the electronic direct reporting CDE center
Have international/domestic senior pharmacovigilance experts to help enterprises quickly establish a pharmacovigilance system
Assist customers in developing and hosting call centers, WeChat, app, websites and other channels to collect drug adverse events
Service personnel with many years of clinical and pharmacovigilance experience can conduct medical coding, medical examination and other case processing services.
Assist in writing FDAAR, DSUR, PSUR and other drug warning reports
Artificial intelligence assists with signal detection and assists customers in developing risk management plans, risk minimization measures, etc.
We can help pharmaceuticals transforming past paper data to electronic, structured and standardized data.
Pharmacovigilance doctor with extensive clinical experience provides professional medical review services for pharmaceutical companies
山东金城医药集团股份有限公司（简称“金城医药”，股票代码：300233）成立于2004年，国家高新技术企业、创业板上市企业。目前，公司拥有北京金城方略医药科技有限公司、北京金城泰尔制药有限公司(原金城朗依制药有限公司）、上海金城药业有限公司、广东金城金素制药有限公司、山东金城医药化工有限公司、山东金城生物药业有限公司、意大利海宝露有限责任公司等多家参控股公司。公司通过“实业+资本”双轮驱动发展模式，已构建形成独具金城特色的医药健康制药工业产业链，业务范围涉及生物制药、头孢类医药中间体、特色原料药、终端制剂、保健品、新材料、新兴高端医疗器械等产业领域，并现已形成年营业收入28亿元、总资产近50亿的产业规模。
Add to Favorites
